We met with Gerard Criner, of Temple University, at ERS 2019 in Madrid, to discuss his presentation on identification of patients with chronic obstructive pulmonary disease who benefit from benralizumab.
1. What is the mechanism of action of benralizumab?
2. Could you tell us a little about the aims and design of the GALATHEA and TERRANOVA clinical studies?
3. What were the findings of these studies?
4. Could these findings be explained by any patient factors?
5. What will be the next step in identifying patients with chronic obstructive pulmonary disease who benefit from benralizumab?
Speaker disclosures: Gerard Criner has received funding from Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, CSA Medical, Eolo Medical, Gala Therapeutics, GlaxoSmithKline, Helios Medical, Merck, Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Olympus, Philips Respironics, PulmonX, Respivant Sciences, Verona Pharma.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Respiratory Society (ERS) International Congress 2019, Madrid, Spain.
Share this Video
Related Videos In COPD
Douglas Mapel, ATS 2021: The Rate of ED Visits in Patients with COPD in the IMPACT Trial
It was a pleasure to meet with Dr Douglas Mapel (Northern Arizona Pulmonary Associates – Critical Care, Flagstaff, AZ, US) to talk around his abstract on ‘Reduction in Emergency Department (ED) Visits in Patients with Chronic Obstructive Pulmonary Disease (COPD): Analysis of the IMPACT Trial.‘, which was presented at ATS 2021 International Conference, 14-19 May, […]
Brian Carlin, CHEST 2020 – New Thoughts in COPD
Brian Carlin (Pittsburgh Critical Care Associates, Pittsburgh, PA, US) talks to us about recent developments in the treatment of COPD and the impact COVID-19 has had on pulmonary rehabilitation services. Questions 1. What have been the most exciting recent developments in inhaled therapies for COPD? (0:20) 2. What factors should physicians consider before prescribing inhaled […]
Peter J Barnes, ERS 2020 – Smart Inhalers for COPD and Asthma
During the ERS International Congress 2020, it was great to catch up with our Editorial Board member, Prof. Peter J Barnes (Imperial College, London, UK), to continue the discussion around Smart Inhalers and how they could help optimise inhaler use in patients. Questions How common is poor adherence and inhaler technique in people with asthma […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!